Acadia Pharmaceuticals Inc.
The Director, AI Engineering leads the strategy and development of Acadia's enterprise AI application and agent ecosystem, overseeing the AI platform and agent framework to deliver secure, scalable, and impactful AI solutions. This hybrid role involves collaborating with IT, cybersecurity, and business stakeholders to ensure governance, compliance, and adoption of AI technologies across the organization.
Headquarters
San Diego, California, United States
Company Size
501-1000 employees
Founded
1993
Acadia Pharmaceuticals is a biopharmaceutical company focused on advancing care for underserved neurological disorders and rare diseases. The company works to translate scientific promise into meaningful innovation by progressing novel therapies from research through clinical development and commercialization. Acadia’s portfolio and pipeline prioritize conditions with high unmet medical need, emphasizing patient-centered development and collaboration to accelerate access to new treatments.
Neo Ivy Capital Management Buys Shares of 62,568 ACADIA Pharmaceuticals Inc. $ACAD
4 days ago
Wolfe Research Notes Conviction-Driven Opportunities in ACADIA Pharmaceuticals Inc.’s (ACAD) Therapeutic Domains
1 week ago
Acadia Pharmaceuticals to Participate at Upcoming Investor Conferences
2 weeks ago
Headquarters
San Francisco, CA
Company Size
201-500 employees
Founded
2018
Industry
Technology
Glassdoor Rating
4.2 / 5
Sarah Johnson
Chief Executive Officer
Michael Chen
Chief Technology Officer
Emily Williams
VP of Engineering
David Rodriguez
VP of Product
Jessica Thompson
Chief Financial Officer
Andrew Park
VP of Sales
View leadership team, funding history,
and employee contacts for Acadia Pharmaceuticals Inc..
Right around the average for this role
Acadia Pharmaceuticals Announces Plan to Request Re-Examination Following Negative CHMP Opinion for Trofinetide for the Treatment of Rett Syndrome
1 week ago